CHEMISTRY MANUFACTURING CONTROL STRATEGY MEETING USA

OUR UNIQUE MEETING FORMAT

Roundtable Discussions

These interactive and informal discussion groups are the hallmark of the meeting. The brightest minds in the industry are brought together in 60-minute sessions that enable participants to share ideas, challenges and lessons learned.

Personalised Agenda

Each delegate receives a personalised agenda with the roundtable discussions that you choose. You only attend sessions and meetings that fit your challenges and interests, ensuring your time out of the office is focused and well-utilised.

One-to-one Meetings

The most effective and time efficient way to assess potential partners at a strategic level. Gain access to our exclusive networking app to identify the people that you need to meet. The app suggests a suitable time and place, all you need to do is grab the coffee.

Strategic Networking

Strategic networking opportunities form a key benefit of the meeting. Our proven format for building and strengthening alliances is underscored by a host of networking programmes, from a buffet breakfast through to evening drinks, make lasting connections that benefit you.

AGENDA

TRACK1 EMERGING BIOPHARMA

> TRACK 2 DRUG PRODUCT

TRACK 3 **TECHNOLOGY TRANSFER & ANALYTICAL**

TRACK 4 INTEGRATED DRUG DEVELOPMENT

TRACK 5 **PROCESS RESEARCH & SCALE-UP**

> TRACK 6 **INTERMIDIATES & API**

TRACK 7 **INVESTMENT & VENTURE CAPITAL**

SPONSORS

f in y http://

HOTEL & TRAVEL

Ist JUNE 2020 PERIDIEN **BOSTON CAMBRIDGE**

CONTRIBUTORS TO THE AGENDA



Nick Vrolijk Vice President **Fusion Pharma**



Stan Russell Executive Director **Alexion Pharmaceuticals**



James Stahl Senior Director Promedior



Qinghai Zhao VP Technical Development & Manufacturing TG Therapeutics



Cui Sheng **Executive Director Boston Pharmaceuticals**



Rick Panicucci SVP CMC **QED** Therapeutics



Padma Malyala **Executive Director** Verve Therapeutics



Gregg Keany VP Product Development Venture NewCo



Praveen Prasanna Sr. Director Technical Operations AVEO Oncology



Theodore Martinot Head of Clinical Development **Infinity Pharmaceuticals**






ROVENTA

		01	02	03		
	TRACK & ROOM	EMERGING BIOPHARMA	DRUG PRODUCT	TECHNOLOGY TI ANALYTI		
	8:00 - 8:30 a.m.					
	8:30 - 9:00 a.m.			WELCOM		
	9:00 - 10:00 a.m.	Comparitive analysis of available CDMOs - does more expensive always mean better?	Advances and Challenges in Nanomedicine and Nanotechnology	Ensuring clarity & comn & expectations for succe transfer during drug o with your CDMO		
		Nick Vrolijk - Vice President Fusion Pharma	Zia Choudry - Director Med. Affairs Sanofi	Nick Dunwoody - \ Tetraphase Phar		
	10:00 - 11:00 a.m.	1-1 MEETING	*10:00-10:20 NETWORKING BREAK			
	11:00 - 12:00 a.m.	ROUNDTABLE TOPIC CONFIRMED FOR SPONSOR	ROUNDTABLE TOPIC CONFIRMED FOR SPONSOR	ROUNDTABI CONFIRMED FO		
	12:00 - 1:00 p.m.	1 - 1 MEETING *12:00-12:20				
	1:00 - 2:00 p.m.	1 - 1 MEETING *13:00-13:20	3 COURSE NETWORKING LUNCH	1-1 MEETING *1		
	2:00 - 2:30 p.m.	KEYNOTE PRESENTATION				
	2:30 - 3:30 p.m.	in-house research for a successful approach to partnership with CMOs		& computer assisted me tools to maximise output		
		Gregg Keany - VP Atlas Venture NewCo	Padma Malyala - Exec. Director Verve Therapeutics	James Stahl - Sr. Dire Promedie		
	3:30 - 3:40 p.m.		AFTERNOON C	COFFEE BREAK		
	3:40 - 4:00 p.m.	1-1 MEETING *20min NETWORKING BREAK				
	4:00 - 5:00 p.m.	Using "one-stop-shop" CDMOs against using suppliers best suited for each step of the process - advantages & disadvantages	Aseptic Manufacturing and Sterile Fill-Finish for Complex Drug Products	Maximising the valu technology transfe facilitating the interpla its integration into the & decision making		
		Alex Goraltchouk - VP Anika Therapeutics Inc.	Praveen Prasanna - Sr. Director AVEO Oncology	Theodor Martin Infinity Pharm		
	5:00 - 5:30 p.m.	INVESTOR	'S PANEL			
I	5:30 - 7:00 p.m.	DRINKS & CANAF	PERECEPTION			

PREVIOUS PAGE

AGENDA AT A GLANCE

C CHEMISTRY MANUFACTURING CONTROL







Nick Vrolijk Vice President **Fusion Pharma**

ROUNDTABLE TOPIC

Comparitive analysis of available CDMOs does more expensive always mean better?

TIME SLOT

9:00 - 10:00 a.m.



Gregg Keany V.P. Product Development Venture NewCo

ROUNDTABLE TOPIC


Strategies to Ensure Strong and Efficient CMC Function at Startup Biotechs.

TIME SLOT

2:30 - 3:30 p.m.

PREVIOUS PAGE

TRACK 1





ROUNDTABLE TOPIC

Advances and Challenges in Nanomedicine and Nanotechnology.

TIME SLOT

9:00 - 10:00 a.m.



Padma Malyala Executive Director Verve Therapeutics

ROUNDTABLE TOPIC


Key Considerations for Intranasal Formulation Development.

TIME SLOT

2:30 - 3:30 p.m.

PREVIOUS PAGE

TRACK 2 **DRUG PRODUCT**



TRACK 3 C CHEMISTRY MANUFACTURING CONTROL **TECHNOLOGY TRANSFER** & ANALYTICAL



ROUNDTABLE TOPIC

How to ensure clarity and communication of goals and expectations for successful technology transfer during drug development with your CDMO

TIME SLOT

9:00 - 10:00 a.m.




James Stahl Sr. Director, Analytical Promedior

ROUNDTABLE TOPIC

Using chromatography modelling software and computer assisted method development tools to maximise output of each experiment

TIME SLOT

2:30 - 3:30 p.m.





TRACK 4 C CHEMISTRY MANUFACTURING CONTROL **TECHNOLOGY TRANSFER** & ANALYTICAL



Rick Panicucci SVP CMC **QED** Therapeutics

ROUNDTABLE TOPIC

Establishing a quality agreement with contracting partners to clearly define the quality system relationship

TIME SLOT

9:00 - 10:00 a.m.



Qinghai Zhao V.P. Technical Development & Manufacturing Forty Seven Inc.


ROUNDTABLE TOPIC

Early stage CMC development strategy to speed IND.



2:30 - 3:30 p.m.

PREVIOUS PAGE









Hemant Kumar SVP Technical Development & Manufacturing Ops. Rentschler

ROUNDTABLE TOPIC

How to generate value for clinical stage companies with CMC strategy for commer cial readiness

TIME SLOT

9:00 - 10:00 a.m.



Cui Sheng Executive Director CMC **Boston Pharmaceuticals**

ROUNDTABLE TOPIC

Scale-Out Biomanufacturing – A Paradign Change to Scale Up.

TIME SLOT

2:30 - 3:30 p.m.

+ INFO A

PREVIOUS PAGE

TRACK 5 **PROCESS RESEARCH** & SCALE-UP

je r-		SPONSOR ROUNDTABLE TOPIC Topic TBC	
	SPEAKER TBC	TIME SLOT	
	TBC BirdoTech	11:00 - 12:00 a.m.	
n		ROUNDTABLE TOPIC Selecting the right route to ensure fast de- velopment and scale-up across all the pro- ject phases and supporting the API projects requirements	
	Greg Liposky SVP Commercial Manufacturing	TIME SLOT	
	Athersys	4:00 - 5:00 p.m.	
	OUR SPEAKERS	PROV INTERNA	





ENTA TIONAL -----

C CHEMISTRY MANUFACTURING CONTROL INTERMIDIATES & API



Stan Russell Executive Director Alexion

ROUNDTABLE TOPIC

Rationale, Strategies and Execution for Developing API & Intermediate Supply.

TIME SLOT

9:00 - 10:00 a.m.




ROUNDTABLE TOPIC

Addressing a wide range of API crystallization and early formulation challenges for drug development programs

TIME SLOT

2:30 - 3:30 p.m.

TRACK 6





1C CHEMISTRY MANUFACTURING CONTROL INVESTMENT & VENTURE

Introducing The New 'Investment & Venture Capital' Track - Proventa International's latest evolutionary step in developing our signature Strategy Meetings. Now not only providing essential operational strategy solutions but also aiding in equally important fund raising and investment seeking strategy.



ROUNDTABLE TOPIC

Allocating an adequate yet conservative CMC budget from investment fund, investor recommendations.

TIME SLOT

9:00 - 10:00 a.m.

SPEAKER TBC TBC TBC

ROUNDTABLE TOPIC


How a shared-risk partnership model can reduce the cost of outsourcing manufacturing - advantages and disadvantages.

TIME SLOT

2:30 - 3:30 p.m.

PREVIOUS PAGE

TRACK 7 CAPITAL








BirdoTech is a chemistry services CRO head quartered in Shanghai China. With clients a cross North America, Europe, and Asia, BirdoTech delivers quality products with utmost stringent criteria while meeting demanding timelines. Our laboratories are equipped with the latest in advanced instrumentations to provide reliable data that are critical for decision-making. To meet our clients' demand, we employ >100 scientists and expanded our R&D labs in Shanghai and Xi'an to 4,000 m2. Further expansion with pilot plants are in Baiyin, Gansu and Jining, Shandong.



SPONSORS

CO-HOST





Sai Life Sciences provides services to our pharma innovator partners, which accelerate the discovery, development and manufacture of complex small molecule therapeutics. Our clients gain clear competitive advantages through shorter time to market and risk minimization using our integrated and high-quality scientific services. Established in 1999, Sai has ;2,000 employees located at 4 R&D and manufacturing sites in India. Sai has focused on building expert core capabilities in all areas of chemistry from hit discovery to GMP manufacturing. Sai also provides high-value integrated services in pharmacology, DMPK, toxicology and formulation development to better support the increasing needs of our customers.

EXHIBITOR



GO TO MENU





LeMERIDIEN

VISIT WEBSITE

20 Sidney Street, Cambridge, Massachusetts 02139 USA

LOCAL AREA

MAP & TRAVEL

E-MAIL FOR +INFO emilia@proventainternational.com

PREVIOUS PAGE

GO TO MENU



